Loading…
Citius Pharmaceuticals, Inc. is projected to decline to $0.672 by 2027, a -3% move from its current price of $0.69. CTXR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.645 | $0.6904 | $0.7389 | +0.05% |
| May 30 | $0.6274 | $0.6907 | $0.7604 | +0.11% |
| May 31 | $0.6144 | $0.6911 | $0.7774 | +0.16% |
| Jun 1 | $0.6036 | $0.6915 | $0.7921 | +0.21% |
| Jun 2 | $0.5943 | $0.6918 | $0.8054 | +0.27% |
| Jun 3 | $0.5861 | $0.6922 | $0.8176 | +0.32% |
| Jun 4 | $0.5786 | $0.6926 | $0.829 | +0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5786 | $0.6926 | $0.829 | +0.37% |
| Week 2 | $0.5391 | $0.6952 | $0.8964 | +0.75% |
| Week 3 | $0.511 | $0.6977 | $0.9527 | +1.12% |
| Week 4 | $0.4888 | $0.7003 | $1.00 | +1.50% |
| Week 5 | $0.4702 | $0.703 | $1.05 | +1.88% |
| Week 6 | $0.4542 | $0.7056 | $1.10 | +2.26% |
| Week 7 | $0.4401 | $0.7082 | $1.14 | +2.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR is a Healthcare stock currently trading around the $0.7011 level, with a market cap of $19.25M and a ranking of 4954.
The near-term price action is framed by a 30-day range, indicating volatility within $0.4353 to $1.13. The current positioning reflects a small-cap profile with a mixed near-term setup.
Looking further ahead, the forecast shows a mixed long-term path, with bearish momentum through 2030 and a turn toward bullish conditions in later years, underscoring an uneven but potentially upside-driven multi-year outlook.
A major floor 55.0% below — a decisive break under it would weaken the trend.
The nearest floor, 23.6% below — buyers have tended to step in here.
The nearest ceiling, 35.2% above — a clean break opens room to run.
A major ceiling 62.7% above — clearing it would confirm fresh momentum.
Key CTXR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CTXR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6682 | Buy | $0.6729 | Buy |
| MA 10 | $0.6492 | Buy | $0.6612 | Buy |
| MA 20 | $0.6546 | Buy | $0.6746 | Buy |
| MA 50 | $0.7428 | Sell | $0.729 | Sell |
| MA 100 | $0.7802 | Sell | $0.8194 | Sell |
| MA 200 | $1.01 | Sell | $1.29 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.12 | Neutral |
| Stoch RSI (14) | 93.97 | Sell |
| CCI (20) | 53.71 | Neutral |
| Williams %R (14) | -15.54 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 7.81 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 84.46 | Sell |
| TRIX (15) | -0.78 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 48.83 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.71 | Sell |
| ADX (14) | 12.42 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL, with an RSI14 reading of 50.
The stock trades relative to key averages, with the SMA50 at $0.7519 and the SMA200 at $1.02. Support is identified at $0.527 and resistance at $0.933, framing a narrow near-term range ahead of broader price action. The 30-day range extends from $0.4353 to $1.13, highlighting notable volatility for CTXR.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.527 | $0.69 | $0.948 | 0% | Neutral | |
| $0.4836 | $0.672 | $1.01 | -3% | Neutral | |
| $0.4172 | $0.6152 | $0.9834 | -11% | Neutral | |
| $0.3812 | $0.5917 | $0.9917 | -14% | Neutral | |
| $0.3487 | $0.5672 | $0.9888 | -18% | Bearish | |
| $0.3782 | $0.6428 | $1.16 | -7% | Neutral | |
| $0.4893 | $0.8672 | $1.61 | +26% | Bullish | |
| $0.4765 | $0.8793 | $1.68 | +27% | Bullish | |
| $0.4383 | $0.8414 | $1.65 | +22% | Bullish | |
| $0.3915 | $0.7811 | $1.56 | +13% | Neutral | |
| $0.5577 | $1.24 | $2.73 | +80% | Bullish | |
| $0.6785 | $1.51 | $3.47 | +119% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.527 | $0.69 | $0.814 | +0.00% |
| June 2026 | $0.5657 | $0.6785 | $0.8431 | -1.67% |
| July 2026 | $0.5938 | $0.7243 | $0.9231 | +6.75% |
| August 2026 | $0.5939 | $0.734 | $0.9537 | +1.35% |
| September 2026 | $0.5642 | $0.7051 | $0.9304 | -3.95% |
| October 2026 | $0.5676 | $0.7166 | $0.959 | +1.64% |
| November 2026 | $0.5775 | $0.7358 | $0.9967 | +2.67% |
| December 2026 | $0.5384 | $0.692 | $0.948 | -5.96% |
Click any year to see its month-by-month CTXR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Citius Pharmaceuticals, Inc.'s 2026 outlook centres on $0.69, within a $0.527 to $0.948 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CTXR could reach as high as $1.01, with a base case around $0.672 and support toward $0.4836 — roughly -3% from $0.69. A consolidation phase looks the most probable path here.
Expect CTXR to range from $0.4172 to $0.9834 through 2028. The $0.6152 average target implies a -11% move from current prices. That is -8% versus the projected 2027 average. Price action looks broadly range-bound.
The CTXR price prediction for 2029 points to an average of $0.5917 (low $0.3812, high $0.9917) — a potential decline of -14% on today's $0.69. A consolidation phase looks the most probable path here.
In 2030, CTXR is projected to trade between $0.3487 and $0.9888, averaging $0.5672 — a potential decline of -18% from today's $0.69. That is -4% versus the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Citius Pharmaceuticals, Inc.'s 2031 outlook centres on $0.6428, within a $0.3782 to $1.16 range. That is up +13% on the projected 2030 average. That marks a -7% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, CTXR could reach as high as $1.61, with a base case around $0.8672 and support toward $0.4893 — roughly +26% from $0.69. Momentum favours further upside here.
Expect CTXR to range from $0.4765 to $1.68 through 2033. The $0.8793 average target implies a +27% move from current prices. That is up +1% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CTXR price prediction for 2034 points to an average of $0.8414 (low $0.4383, high $1.65) — a potential gain of +22% on today's $0.69. Momentum favours further upside here.
In 2035, CTXR is projected to trade between $0.3915 and $1.56, averaging $0.7811 — a potential gain of +13% from today's $0.69. That is -7% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Citius Pharmaceuticals, Inc.'s 2040 outlook centres on $1.24, within a $0.5577 to $2.73 range. That is up +59% on the projected 2035 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2050, CTXR could reach as high as $3.47, with a base case around $1.51 and support toward $0.6785 — roughly +119% from $0.69. Buyers look set to stay in control over this stretch.
Investing $1,000 in CTXR today (≈ 1,449.275362 CTXR) could be worth
$2,185.28
+$1,185.28 (+119%) by 2050 · US Dollar
Based on the average projected CTXR price of $1.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CTXRwould be worth at today's price.
$1,000 invested in CTXR on May 27, 2025 (≈ 1,406.469711 CTXR) would be worth
$970.46
-$29.54 (-3.0%) today · 0.97× · US Dollar
Based on a CTXR entry price of $0.711 vs. today's $0.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.58 | $1,189.66 | +19.0% |
| 1 month ago | $0.691 | $998.55 | -0.1% |
| 3 months ago | $0.754 | $915.12 | -8.5% |
| 6 months ago | $1.44 | $479.17 | -52.1% |
| 1 year ago | $0.711 | $970.46 | -3.0% |
| All time (5.0y) ago | $58.75 | $11.74 | -98.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CTXR forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $38.43M
The year-by-year forecast shows a progression from neutral to bearish early on, then a shift to bullish momentum in the later years. In 2026 the avg price is $0.7011 with 0% ROI, and in 2027 the avg is $0.6841 with a -2.4% ROI. 2028’s avg is $0.629 with a -10.3% ROI, followed by 2029 at an avg of $0.5928 and a -15.4% ROI, and 2030 at an avg of $0.5861 with a -16.4% ROI.
From 2032 onward the forecast turns bullish, with 2032 avg $0.8868 (max $1.65, ROI 26.5%), 2033 avg $0.9107 (max $1.74, ROI 29.9%), and 2034 avg $0.8585 (max $1.68, ROI 22.4%), then 2035 avg $0.79 (max $1.58, ROI 12.7%).
The longer horizon shows stronger upside, with 2040 avg $1.28 (max $2.81, ROI 82.5%) and 2050 avg $1.55 (max $3.57, ROI 121.5%). These are estimates and illustrate potential paths, not guarantees, with risk and uncertainty inherent in small-cap healthcare equities.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $0.5861, with a min of $0.3601 and a max of $1.02. The ROI is -16.4% and the sentiment is BEARISH.
Yes. The 2032 forecast lists a max of $1.65, with an avg of $0.8868 and a min of $0.5001. The ROI is 26.5% and the sentiment is BULLISH.
The 30-day picture is NEUTRAL, with RSI(14) at 50. The SMA50 is $0.7519 and the SMA200 is $1.02. Support sits at $0.527 and resistance at $0.933. The 30-day range is $0.4353 to $1.13.
The current price is $0.7011 and the market cap is $19.25M.
For 2040 the avg is $1.28 (max $2.81, ROI 82.5%, sentiment BULLISH) and for 2050 the avg is $1.55 (max $3.57, ROI 121.5%, sentiment BULLISH).
Citius Pharmaceuticals, Inc. Community Discussion
0Share your Citius Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.